Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 31, 2024 - Issue 2
257
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy

, , , , , , , , , , , , , , & show all
Pages 145-147 | Received 28 Jul 2023, Accepted 07 Nov 2023, Published online: 09 Dec 2023

References

  • Kumar N, Zhang NJ, Cherepanov D, et al. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis. 2022;17(1):278. Jul 19 doi:10.1186/s13023-022-02414-6.
  • Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26. Jul 2 doi:10.1161/CIRCULATIONAHA.118.038169.
  • Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. Sep 13 doi:10.1056/NEJMoa1805689.
  • Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. Jul 5 doi:10.1056/NEJMoa1716153.
  • Elliott P, Drachman BM, Gottlieb SS, et al. Long-Term survival With tafamidis in patients With transthyretin amyloid cardiomyopathy. Circulation Heart Failure. 2022;15(1):e008193. Jan
  • Rettl R, Mann C, Duca F, et al. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23(6):767–780. Jun 1 doi:10.1093/ehjci/jeab226.
  • Chamling B, Bietenbeck M, Korthals D, et al. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging. Clin Res Cardiol. 2023;112(3):353–362. May
  • Fischer K, Linder OL, Erne SA, et al. Reproducibility and its confounders of CMR feature tracking myocardial strain analysis in patients with suspected myocarditis. Eur Radiol. 2022;32(5):3436–3446. May doi:10.1007/s00330-021-08416-5.
  • Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume With patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14(1):189–199. Jan doi:10.1016/j.jcmg.2020.07.043.
  • Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–1579. Oct 20 doi:10.1161/CIRCULATIONAHA.115.016567.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.